Pain Management

The deadline to submit comments is April 11.

Mouth discomfort can be especially irritating, but there are some products on pharmacy shelves that might be useful.

The panel concludes our discussion with the role healthcare providers play today in the treatment of opioid overdose and what needs to change for the future.

Our experts provide their expertise on Patient Case 2 and how they would proceed with treatment.

Dr Torrington moves on to Patient Case 2, a 49-year-old man found semi-responsive with a suspected opioid overdose.

Combining nonopioid analgesics and nonpharmacologic pain management options with opioid medications can lead to better patient outcomes.

The group discusses Patient Case 1 and how they would treat in this scenario.

Matthew A. Torrington, MD, introduces our first patient case, a 27-year-old man presenting with injuries from a car accident.

Results highlight the impact of education on patient understanding of potential adverse events.

Keeping OTC products near the pharmacy counter creates an opportunity for patient counseling and education.

Patient confidence in CBD products—and pharmacist ability to provide counsel—increased during the study.

In rural settings, patients and providers are frequently reading from different scripts when it comes to managing these conditions

A group of specialists discuss overdoses and treatment with naloxone so family and caregivers are prepared for the future and for treatment.

Dr Kosten describes how to deal with a fentanyl overdose.

Our panel of doctors and pharmacists introduce naloxone, an opioid antagonist, as an option when treating opioid abuse or overdose.

The panel explains the common challenges they find when trying to treat a patient with opioids.

Before seeing a physician, patients can try to treat osteoarthritis pain with OTC remedies.

Four experts delve into pain management and how opioid abuse factors into their decision-making.

A panel of experts discuss the parameters of the opioid epidemic and the role fentanyl plays within it.

The new guidelines come on the heels of the controversial 2016 guidance that placed hard caps on prescribing.

An oral concurrent session at SMFM’s 42nd Annual Pregnancy Meeting highlighted an analysis of pregnancy outcomes after optimal prenatal opioid use disorder care.

Less than 5% of people with migraine have received an accurate diagnosis for this disabling—and painful—disease.

Calcitonin gene-related peptide (CGRP) antagonists are the first class of drugs developed exclusively for migraine prevention.

Preventive medications might be considered in patients with 4 or more migraine days per month.

More than 37 million men, women, and children in the United States are affected by migraine.